INVESTMENT OBJECTIVE

To achieve capital appreciation on an absolute and relative basis over the medium to long-term horizon through investment in Swiss equities with a focus on innovative companies that are leaders in their markets.

PORTFOLIO REVIEW

In July, the last few months' dichotomy between small- and mid-caps on the one hand and large-caps on the other became even more pronounced. The SMI shed 0.7%, weighed down notably by the monthly underperformance of Nestlé (-10%), Richemont (-10%), Sika (-11%) and Givaudan (-11%). Conversely, the SPI Extra gained 2.4%. As of month end, the year-todate performance gap between the two indices stood at around 8%.

The latter part of July saw the release of half-year results by most SPI member companies. As is the case every summer, in a market with low trading volumes, some reports caused sharp price fluctuations, both upwards and downwards.

Of the hundred or so Swiss companies that released their results, 52% posted sales volumes in line with or above expectations, while 48% came in below forecasts. As regards earnings, only 41% of companies exceeded or met expectations, 59% having reported net income below forecasts, often hurt by the weakness of the US dollar.

Although the reasons for the discrepancies between actual and expected results vary from one company to another, a common factor emerges among those that disappointed: the impact of upcoming tariffs. By increasing uncertainty, these tariffs have slowed down activity and postponed certain investment decisions.

The Bruellan Dynamic Swiss fund closed July up 0.4%, slightly outperforming the SPI (-0.1%). Not surprisingly, the top monthly performers were small-cap stocks, led by Basilea (+24%), Swissquote (+21%), Belimo (+18%) and Interroll (+16%). Also noteworthy was the excellent performance of dermatology specialist Galderma (+11%), which benefited from the recent success of two major launches: Nemluvio, for the treatment of certain skin conditions, and the neuromodulator Relfydess. Lastly, Logitech managed a 7% gain, displaying solid resilience in a difficult environment.

Conversely, the sharpest declines were posted by some large-caps, but also our two suppliers to the semiconductor sector: Comet (-17%) and VAT (-14%), which were particularly hurt by their customers' caution and the postponement of major investment projects until the end of the year or even 2026.

NET PERFORMANCE AND ANNUAL PERFORMANCE IN CHF



	Fund	SPI Index	+/-
1 Month	0.5%	-0.1%	0.5%
3 Months	3.5%	0.3%	3.2%
YTD	8.3%	6.8%	1.5%
Since inception	118.8%	105.5%	13.3%

Source: All data and graphs throughout the document from Bruellan

Past performance may not be a reliable guide to future performance. All forms of investment involve risk.

The benchmark index is the SPI Index.

Please refer to the end of the document mentioned for performance comparison purposes

RISK & REWARD

Instit.: 1 ntry/exit fees 0.0% / 0	ary 20 aud Marin Millio	i CFA, CN ns		
omicile Switzerla deception date 19 Janua durrency CHF lead Manager Anick Ba lo-Manager Florian M lund size* CHF 35 M liquidity (sub./red.) Daily lin. Investment Retail: 10 Instit.: 1	ary 20 aud Marin Millio	i CFA, CM ns		
nception date 19 Janua currency CHF ead Manager Anick Ba o-Manager Florian M iquidity (sub./red.) Jaily Jin. Investment Retail: 10 Instit.: 1	ary 20 aud Marin Millio	i CFA, CM ns		
urrency CHF ead Manager Anick Ba o-Manager Florian M und size* CHF 35 M iquidity (sub./red.) Daily lin. Investment Retail: 10 Instit.: 1	aud Marin Millio	i CFA, CM ns		
ead Manager Anick Ba o-Manager Florian M and size* CHF 35 M iquidity (sub./red.) Daily lin. Investment Retail: 10 Instit.: 1	Marin Millio	ns		
o-Manager Florian Mund size* CHF 35 Miquidity (sub./red.) Daily lin. Investment Retail: 10 Instit.: 1	Marin Millio	ns		
ind size* clud size* clud size* clud size* clud size* clud size* CHF 35 M Paily Retail: 10 Instit:: 1 clud size* cl	Millio	ns		
iquidity (sub./red.) Daily				
in. Investment Retail: 10 Instit.: 1 http://exit.fees 0.0% / 0	000 C			
Instit.: 1 ntry/exit fees 0.0% / 0	በበበ ሮ			
ntry/exit fees 0.0% / 0	0000	Retail: 1000 CHF		
),	millio	on CHF		
lanagement fees 1.2%-0.8	0.0% / 0.0%			
	1.2%-0.8%			
erformance fees 20%	20%			
igh Water Mark Yes				
enchmark SPI Index	x			
SIN Retail: Cl	Retail: CH0253810144			
Instit.: Cl	H025	381016		
loomberg Retail: B	Retail: BDFSECA SW			
Instit.: B		Instit.: BDFSECB SW		

^{*} the total strategy size is CHF 66 million

Not all the costs are presented, further information can be found in the prospectus or equivalent


Retail: 2145.96 Instit.: 2187.77

STATISTICS

NAV

	Fund	SPI Index
Leading PE	22.2	18.2
EV/EBITDA	18.4	11.9
P/Book	6.4	1.9
Dividend Yield	2.1%	2.7%
ROE	26.7%	8.5%
Debt/Equity	55.8%	55.8%
Interest Coverage	14.8	8.2
Beta	1.0	1.0
Volatility	14.3%	12.4%

ALLOCATION BY MARKET CAP




BRUELLAN DYNAMIC SWISS EQUITIES

JULY 2025



ALLOCATION BY SECTOR



FUND COMPLEMENTARY DETAILS

CACEIS (Switzerland) SA,
Administrator Rte de Signy 35

Rte de Signy 35, CH-1260 Nyon

Investment Manager Bruellan SA Custodian CACEIS (Swi

CACEIS (Switzerland) SA,

Rte de Signy 35, CH-1260 Nyon

Auditor KPMG

TOP 10 HOLDINGS

	Sector	Weight
NESTLE SA-REG	Consumer Staples	8.5%
NOVARTIS AG-REG	Health Care	8.2%
ROCHE HOLDING AG-GENUSSCHEIN	Health Care	8.1%
BELIMO HOLDING AG-REG	Industrials	4.9%
LONZA GROUP AG-REG	Health Care	4.4%
GALDERMA GROUP AG	Health Care	4.4%
ZURICH INSURANCE GROUP AG	Financials	4.3%
GEBERIT AG-REG	Industrials	4.3%
SWISSQUOTE GROUP HOLDING-REG	Financials	3.9%
CIE FINANCIERE RICHEMO-A REG	Consumer Discretionary	3.4%
Total		54.5%
Total number of Holdings		26

CONTACT

BRUELLAN SA Rue Pécolat 1 CH-1201 Genève Tél: +41 22 817 18 55 bam@bruellan.ch

Disclaimer. Bruellan SA has a FINMA authorisation as a collective asset manager. This publication is a promotional document within the meaning of art. 68 LSFin, it is not independent research. It is solely intended to provide information on the funds in question and does not constitute an offer to buy or sell, investment advice or a recommendation regarding investment or other decisions. The funds may be subject to sales restrictions applicable to certain countries or individuals. It is the responsibility of each investor to be aware of the terms and conditions applicable to each product. This publication is directed only at persons authorised to receive it under the regulations in force in their country of domicile.

The information contained herein is based on sources believed to be reliable. This is a marketing communication. Bruellan cannot guarantee its completeness and accuracy and accepts no liability for any damage

The information contained herein is based on sources believed to be reliable. This is a marketing communication. Bruellan cannot guarantee its completeness and accuracy and accepts no liability for any damage that may result from actions taken on the basis of the information published in this document. The information reflects the situation on the day of publication. We have classified this product as 5 out of 7, which is a medium - high risk class. Please refer to the prospectus for more information on the specific risks relevant to this product not included in the summary indicator.

Investment decisions should always be made on the basis of a detailed source of information, in particular the fund prospectus. The prospectus, the articles of association, the key information document, the subscription form and the latest annual and semi-annual reports can be obtained (free of charge) from the Swiss representative, Fund Partner Solutions (Suisse) SA, 60, route des Acacias, 1211 Geneva. Please refer to the prospectus and information document of the fund before making any final investment decisions. You can obtain a summary of investors rights to the following link: https://www.pictet.com/content/dam/www/documents/legal-and-notes/fundpartner-solutions/fps-summary-of-Investors-rights.pdf. The decision to invest in the promoted fund should take into account all the